The Prognostic and Predictive Value of EGFR and HER-2 in Advanced Non-small Cell Lung Cancer Patients Who Are Treated with Cisplatin and Paclitaxel
Journal of Lung Cancer 2009³â 8±Ç 1È£ p.13 ~ p.20
À¯Áø¿µ(Yoo Jin-Young) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
½Éº´¿ë(Shim Byoung-Yong) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
°¼®Áø(Kang Seok-Jin) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ º´¿øº´¸®Çб³½Ç
Abstract
Purpose: Although both platinum-based drugs and third-generation drugs are commonly used as first-line therapy for patients with advanced, unresectable non-small cell lung cancer, their effectiveness and clinical outcomes vary. We investigated whether epidermal growth factor receptor (EGFR) and HER-2 were correlated with the chemoresponse and survival after treatment with a cisplatin plus paclitaxel regimen.
Materials and Methods: Forty-nine tumors were analyzed by chromogenic in situ hybridization (CISH) for EGFR and HER-2 gene amplification.
Results: Twenty-eight patients (57%) achieved a partial response (PR), 13 (27%) showed stable disease (SD) and 8 (16%) had progressive disease (PD). EGFR and HER-2 amplification was identified in 43% and 57% of the tumors, respectively. EGFR amplification revealed no association with either a chemoresponse or survival, whereas HER-2 was amplified more frequently in the patients with PD (88% vs. 54%, respectively, p=0.06) and in the patients with shorter survival (12 months vs. 20 months respectively, p=0.027).
Conclusion: The evaluation of HER-2 gene amplification is a promising approach for identifying those patients who are most likely to benefit from combination chemotherapy with cisplatin and paclitaxel.
Å°¿öµå
Non-small cell lung carcinoma, Epidermal growth factor receptor, HER-2, Chromogenic in situ hybridization
KMID :
0982820090080010013
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
º»¿¬±¸¿¡¼ Epidermal growth factor receptor (EGFR)Àº Á¾¾çÀÇ ¹ÝÀÀÀ̳ª »ýÁ¸°ú Á÷Á¢ÀûÀÎ ¿¬°ü¼ºÀ» º¸ÀÌÁö ¾Ê¾ÒÀ¸³ª, HER-2´Â Á¾¾çÀÇ ¹ÝÀÀ»Ó ¾Æ´Ï¶ó ȯÀÚÀÇ »ýÁ¸ ±â°£°úµµ ¿¬°üÀÌ ÀÖ´Ù